{"nctId":"NCT00742391","briefTitle":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","startDateStruct":{"date":"2008-09"},"conditions":["Actinic Keratoses"],"count":255,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: PEP005 (ingenol mebutate) Gel"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle gel"]}],"interventions":[{"name":"PEP005 (ingenol mebutate) Gel","otherNames":[]},{"name":"Vehicle gel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be male or female and at least 18 years of age.\n* Female patients must be of:\n* Non-childbearing potential;\n* Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.\n* 4 to 8 AK lesions on non-head locations.\n\nExclusion Criteria:\n\n* Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.\n* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.\n* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patients With Complete Clearance of Actinic Keratosis (AKs)","description":"Complete clearance rate of actinic keratosis (AK) lesions defined as the proportion of patients with no clinically visible AK lesions in the selected treatment area.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With Partial Clearance of Actinic Keratosis (AKs)","description":"Partial clearance rate of AK lesions defined as the proportion of patients with a 75% or greater reduction in the number of actinic keratosis (AK) lesions identified at baseline in the selected treatment area.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":125},"commonTop":[]}}}